Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2021 16:05 ET | Source: NeuBase Therapeutics, Inc.

NeuBase to Present at the Jefferies London Healthcare Conference

PITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
September 28, 2021 16:05 ET | Source: NeuBase Therapeutics, Inc.

NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using...
September 15, 2021 16:05 ET | Source: NeuBase Therapeutics, Inc.

NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
September 14, 2021 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer

PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
September 01, 2021 16:05 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference

PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
August 12, 2021 16:01 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights

Further demonstrated broad potential of novel genetic medicine platform with in vivo data in three diseases driven by different genetic mechanisms of diseasePresented preclinical data showing...
June 08, 2021 12:30 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

Data presented today at NeuBase’s R&D Day show functional rescue of myotonic dystrophy type 1 (DM1) phenotype in vivo after subcutaneous dosing; positions program to enter the clinic in CY...
June 02, 2021 09:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th

Company to present new preclinical data in myotonic dystrophy type 1 to support a path to enter the clinic in 2022, as well as provide updates on the Huntington’s disease program and unveil a new...
May 25, 2021 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer

PITTSBURGH, May 25, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of...
May 20, 2021 08:00 ET | Source: NeuBase Therapeutics, Inc.

NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer

PITTSBURGH, May 20, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of...